NO20070930L - Stabiliserende formuleringer - Google Patents

Stabiliserende formuleringer

Info

Publication number
NO20070930L
NO20070930L NO20070930A NO20070930A NO20070930L NO 20070930 L NO20070930 L NO 20070930L NO 20070930 A NO20070930 A NO 20070930A NO 20070930 A NO20070930 A NO 20070930A NO 20070930 L NO20070930 L NO 20070930L
Authority
NO
Norway
Prior art keywords
protein
storing
methods
relatively low
stabilizing formulations
Prior art date
Application number
NO20070930A
Other languages
English (en)
Norwegian (no)
Inventor
Li Li
Angela Kantor
Shannon B Macmillan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070930L publication Critical patent/NO20070930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20070930A 2004-08-13 2007-02-19 Stabiliserende formuleringer NO20070930L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60131104P 2004-08-13 2004-08-13
PCT/US2005/028861 WO2006020935A2 (en) 2004-08-13 2005-08-12 Stabilizing formulations

Publications (1)

Publication Number Publication Date
NO20070930L true NO20070930L (no) 2007-05-14

Family

ID=35908214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070930A NO20070930L (no) 2004-08-13 2007-02-19 Stabiliserende formuleringer

Country Status (18)

Country Link
US (1) US8871201B2 (enExample)
EP (1) EP1784219B1 (enExample)
JP (1) JP4948407B2 (enExample)
KR (1) KR20070092197A (enExample)
CN (1) CN101022831A (enExample)
AR (1) AR051009A1 (enExample)
AU (1) AU2005272603A1 (enExample)
BR (1) BRPI0514340A (enExample)
CA (1) CA2575870A1 (enExample)
CR (1) CR8904A (enExample)
EC (1) ECSP077246A (enExample)
ES (1) ES2637854T3 (enExample)
IL (1) IL181265A0 (enExample)
MX (1) MX2007001599A (enExample)
NO (1) NO20070930L (enExample)
RU (1) RU2007109062A (enExample)
TW (1) TW200621282A (enExample)
WO (1) WO2006020935A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3673919A1 (en) 2005-06-14 2020-07-01 Amgen Inc. Self-buffering protein formulations
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
KR101317235B1 (ko) * 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
EP1950225A1 (de) * 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
KR20100014674A (ko) 2007-03-29 2010-02-10 아보트 러보러터리즈 결정성 항-사람 ｉｌ-12 항체
NZ585702A (en) * 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
CA2840711C (en) * 2011-07-01 2023-10-17 Biogen Idec Ma Inc. Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
WO2013082427A1 (en) 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP3431104A1 (en) * 2012-03-26 2019-01-23 Sanofi Stable igg4 binding agent formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP3065780A1 (en) 2013-11-04 2016-09-14 Pfizer Inc. Anti-efna4 antibody-drug conjugates
PT3834824T (pt) 2014-03-28 2025-11-18 Univ Duke Tratamento do cancro da mama positivo para o receptor de estrogénio utilizando um modulador seletivo do recetor de estrogénio
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN107076759A (zh) * 2014-07-21 2017-08-18 非链实验室 从δg的浓度依赖性来测定蛋白质聚集
CA2984357A1 (en) 2015-04-29 2016-11-03 Radius Pharmaceuticals, Inc. Methods for treating cancer
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
HUE052805T2 (hu) 2016-08-18 2021-05-28 Regeneron Pharma Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
MX383786B (es) 2017-01-05 2025-03-14 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
AU2019297421B2 (en) 2018-07-04 2024-08-29 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
MX2021009569A (es) 2019-02-12 2021-09-08 Radius Pharmaceuticals Inc Procesos y compuestos.
EP4142792A4 (en) * 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
WO2022154529A1 (ko) * 2021-01-14 2022-07-21 한올바이오파마주식회사 안정화제를 사용하지 않고도 안정한, 탄파너셉트를 포함하는 안과용 조성물
CN115541895B (zh) * 2022-11-29 2023-05-19 天津德祥生物技术股份有限公司 一种提高微流控反定检测卡灵敏度的配方液及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3176517D1 (en) 1980-04-24 1987-12-17 Beecham Group Plc Beta-lactam compounds, their preparation and use
GB8518416D0 (en) 1985-07-22 1985-08-29 Beecham Group Plc Compounds
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
ES2477996T3 (es) * 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003057163A2 (en) * 2002-01-03 2003-07-17 Smithkline Beecham Corporation Methods for preparing immunoconjugates
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2535804A1 (en) * 2003-08-14 2005-03-03 Wyeth Anti-lewis y anti-idiotypic antibodies and uses thereof
BRPI0515113A (pt) 2004-09-10 2008-07-01 Wyeth Corp anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina

Also Published As

Publication number Publication date
IL181265A0 (en) 2007-07-04
TW200621282A (en) 2006-07-01
WO2006020935A2 (en) 2006-02-23
ES2637854T3 (es) 2017-10-17
JP4948407B2 (ja) 2012-06-06
US8871201B2 (en) 2014-10-28
MX2007001599A (es) 2007-04-10
ECSP077246A (es) 2007-05-30
AU2005272603A1 (en) 2006-02-23
KR20070092197A (ko) 2007-09-12
AR051009A1 (es) 2006-12-13
US20060115472A1 (en) 2006-06-01
CA2575870A1 (en) 2006-02-23
EP1784219A4 (en) 2010-02-17
EP1784219B1 (en) 2017-05-17
CR8904A (es) 2007-08-28
EP1784219A2 (en) 2007-05-16
BRPI0514340A (pt) 2008-06-10
RU2007109062A (ru) 2008-09-20
JP2008515775A (ja) 2008-05-15
WO2006020935A3 (en) 2007-03-08
CN101022831A (zh) 2007-08-22

Similar Documents

Publication Publication Date Title
NO20070930L (no) Stabiliserende formuleringer
Simpson Stabilization of proteins for storage
Cuin et al. Amino acids regulate salinity-induced potassium efflux in barley root epidermis
JP2008515775A5 (enExample)
Hirano et al. Arginine increases the solubility of coumarin: comparison with salting-in and salting-out additives
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
NO20085131L (no) Lyofiliserte preparater av anti-EGFR-antistoffer
CH688194A5 (fr) Composition stabilisée de troponine pour immunoessais et procédé de stabilisation de troponine pour immunoessais.
WO2007037795A3 (en) Stable aqueous protein or antibody pharmaceutical formulations and their preparation
Clifford et al. Crustacean zooplankton release copious amounts of dissolved organic matter as taurine in the ocean
Hou et al. Analysis of glutathione in biological samples by HPLC involving pre-column derivatization with o-phthalaldehyde
Di Martino Bap: a new type of functional amyloid
Cleal et al. Modification of fetal plasma amino acid composition by placental amino acid exchangers in vitro
Dar et al. Counteraction of the deleterious effects of urea on structure and stability of mammalian kidney proteins by osmolytes
JP2014501526A5 (enExample)
EP1664123A4 (en) Large scale preparation of alpha-1 proteinase inhibitor and use thereof
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
Tsikas Extra-platelet low-molecular-mass thiols mediate the inhibitory action of S-nitrosoalbumin on human platelet aggregation via S-transnitrosylation of the platelet surface
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
EP3178927B1 (en) Protein-stabilizing agent and protein-stabilizing method
JP2009002709A (ja) 蛋白質を含む液状組成物中における蛋白質の安定化方法
Judycka et al. Cryopreserved rainbow trout semen can be used for the fertilization of up to 8000 eggs in a single application
Steele et al. Dogmas and controversies in the handling of nitrogenous wastes: osmoregulation during early embryonic development in the marine little skate Raja erinacea; response to changes in external salinity
ES2321373T3 (es) Procedimiento para la estabilizacion de proteinas en mezclas complejas durante su almacenamiento en disolventes acuosos.
Pérez et al. Restoration of photosystem II photochemistry and carbon assimilation and related changes in chlorophyll and protein contents during the rehydration of desiccated Xerophyta scabrida leaves

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application